Sanofi, rival drugmakers Lilly, Boehringer settle suit allowing rival to Lantus insulin in US This product image provided by Sanofi shows Lantus SoloStar, the French drugmaker's once-daily insulin in ...

Sanofi has put off a biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering ...

More Americans with diabetes will get a break on their insulin costs in 2024. Sanofi is joining the nation's two other major insulin manufacturers in offering either price caps or savings programs ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Civica Rx, a nonprofit generic drug maker backed by hospitals, insurers and philanthropies, announced Thursday that it plans to manufacture and sell insulin for no more than $30 a vial. It is expected ...

When the US Food and Drug Administration (FDA) approved Semglee, the first interchangeable biosimilar insulin, the agency pitched it as having the potential to be less costly than insulins currently ...

TRENTON, N.J. — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...